Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
Top Cited Papers
Open Access
- 1 October 2007
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 92 (10) , 1399-1406
- https://doi.org/10.3324/haematol.11534
Abstract
There are a number of reports in literature data on the long-term outcomes of patients with multiple myeloma treated with high-dose therapy and autologous stem cell transplantation (HDT/SCT). While in general these data support the association between maximal tumor response and overall survival or progression-free survival after HDT/SCT, some trials have failed to find such correlation and there is no recent comprehensive literature analysis of this issue. We, therefore, performed a comprehensive literature review to identify prospective and retrospective studies on HDT/SCT in frontline multiple myeloma in which long-term outcomes were reported according to best tumor response observed. Following a prospectively defined search strategy we identified 21 studies (10 prospective and 11 retrospective studies) in which outcomes of 4,990 HDT/SCT patients according to their best tumor response were reported. The majority of these studies indicated a correlation between maximal response during or after HDT/SCT and long-term outcomes (overall survival and event-free/progression-free survival). The conclusions in individual studis report on the association between maximal response following induction therapy and long-term outcomes were more heterogeneous, possibly due to the low rate of complete response after standard induction therapy in each individual study. We, therefore, performed two types of meta-analyses, one based on the p-values reported for these associations in the individual studies, and one based on the primary response and outcome data provided in the individual studies. Both meta-analyses indicated highly significant associations between maximal response (complete response/near complete response/very good partial response) during or after HDT/SCT and long-term outcomes (overall survival and event-free/progression-free survival). Both meta-analyses also provided evidence of highly significant associations between maximal response following induction therapy and long-term outcomes (overall survival and event-free/progression-free survival).Keywords
This publication has 23 references indexed in Scilit:
- Mouse plasmacytoid dendritic cells derive exclusively from estrogen-resistant myeloid progenitorsBlood, 2006
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2006
- High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-AutogreffeJournal of Clinical Oncology, 2005
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- Randomized trial experience of the Intergroupe Francophone du MyélomeSeminars in Hematology, 2001
- Methodologic Guidelines for Review PapersJNCI Journal of the National Cancer Institute, 1997
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Systematic Reviews: Checklists for review articlesBMJ, 1994
- The Medical Review Article: State of the ScienceAnnals of Internal Medicine, 1987